A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic Sclerosis
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Brodalumab (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kyowa Kirin
Most Recent Events
- 11 Jul 2025 Status changed from active, no longer recruiting to completed.
- 24 Dec 2024 Planned End Date changed from 28 Feb 2025 to 1 Apr 2025.
- 16 Jul 2024 Planned End Date changed from 29 Feb 2024 to 28 Feb 2025.